News & Media
Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officer
Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global Scientific Affairs at Bausch + Lomb, overseeing the medical and clinical development of the …
read moreVIDEO: Ace Vision Group provides update on presbyopia laser development
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, AnnMarie Hipsley, DPT, PhD, and Alex Lopez of Ace Vision Group provide an update on the development of the VisioLite ophthalmic laser for presbyopia. The company is in a Series B2 round of funding.
read moreAce Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read moreAce Vision Group Adds Four Ophthalmologists to Medical Advisory Board; Launches New Corporate and Medical Affairs Websites
Ace Vision Group announced the addition of Cathleen McCabe, MD; James Katz, MD; Ehsan Sadri, MD; and Dagny Zhu, MD, to its medical advisory board. These prominent ophthalmologists will contribute expertise to advance the development and implementation of novel solutions for eye health, specifically Laser Scleral Microporation (LSM), a laser therapeutic designed to rejuvenate the …
read moreDynamic range of focus recovery in presbyopes after laser scleral microporation
While considered by many to be a “normal process of aging,” the loss of the dynamic focusing function of the eye, presbyopia, is a progressive disease of ocular aging. Presbyopia affects approximately 1.8 billion people globally.1 Estimated global annual productivity losses are approximately 0.037% of the global gross domesticproduct in presbyopic adults less than 65 years …
read moreNew-generation software further improves precision of laser scleral microporation
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Luca Gualdi, MD, speaks about the latest advances in laser scleral microporation. Laser scleral microporation (LSM, Ace Vision Group) is a treatment that restores accommodation in presbyopic patients by uncross-linking the scleral tissue that becomes stiff with age. It does so by performing arrays of micropores in …
read more